

Stockholm, 2018-12-10

## PRESS RELEASE

### **Signed MTA with Asian pharmaceutical company regarding QPG-1029 (peg-liraglutide)**

**QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, so called biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. After receiving positive pre-clinical trial results for QPG-1029, QuiaPEG today announces that it has signed a Material Transfer Agreement (MTA) with an Asian pharmaceutical company regarding the QPG-1029 drug project (peg-liraglutid), which has blockbuster<sup>1</sup> potential in the indications diabetes and overweight.**

QuiaPEG reports successful pre-clinical outcomes that, amongst other things shows that QPG-1029, which is an improved version of the original drug liraglutid<sup>2</sup>, has significantly longer half-life than the original form of liraglutide. Liraglutid is an approved drug with annual sales of approximately USD 4 billion and the basic patent expires in 2022. Liraglutid has been developed by the global pharmaceutical company Novo Nordisk and is sold under the brands Victoza™ and Saxenda™ within the indications type 2 diabetes and obesity. The original drug Liraglutide is injected daily while the QPG-1029 research results indicate a possible weekly dose, i.e. a significant improvement for patients.

Under the present agreement QuiaPEG provides substance QPG-1029 to the Asian pharmaceutical company, which will perform pre-clinical trials in its own model systems to study the effects of QPG-1029. If the tests are successful, both parties agree to enter licensing discussions. For reasons of competition, the Asian pharmaceutical company's identity and financial commitments are currently held confidential.

- *"We are very pleased to have already signed an MTA for QPG-1029, which has a very large market potential. The agreement shows the attractiveness of Uni-Qleaver® and the projects it can generate in the future. Our hope is that the agreement will lead to a licensing agreement and continued research collaboration in the next year," said Marcus Bosson, CEO.*

<sup>1</sup> A drug that reaches over one billion dollars in annual sales.

<sup>2</sup> Liraglutide is a so-called GLP-1 analog (glucagon-like peptide) that binds to and activates the GLP-1 receptor, resulting in glucose-dependent, increased insulin secretion while reducing glucagon production. This leads to a blood sugar lowering effect. The blood glucose lowering mechanism also includes a minor retardation of stomach emptying. Liraglutide reduces body weight and body fat mass through mechanisms that reduce hunger and lower energy intake. (source: Läkemedelsverket)

For further information contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53    e-mail: [marcus.bosson@quiapeg.com](mailto:marcus.bosson@quiapeg.com)    [www.quiapeg.com](http://www.quiapeg.com)

*This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the above named contact person, for publication on December 10th, 2018.*